Narrative review: senolytics, inflammaging and age-related bone loss in osteoporosis
This narrative review links immunosenescence and inflammaging to age-related bone loss and weighs preclinical and early clinical evidence for senolytics in osteoporosis. It notes that direct evidence of selective removal of senescent immune-cell subsets in osteoporotic bone marrow is lacking and proposes a research roadmap. [1]
Automatic summary · not editorially reviewed
The key findings
The review links inflammaging to age-related bone loss by reshaping the bone marrow immune microenvironment. [1]
Preclinical studies with dasatinib plus quercetin, fisetin and bone-targeted platforms improved certain skeletal parameters in several models. [1]
Early clinical evidence supports feasibility but does not establish senolytics as routine osteoporosis therapy. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- People with osteoporosis and preclinical models of aging, postmenopausal osteoporosis and radiotherapy-associated bone loss
- Summary based on
- Study abstract
- Original publication
- August 24, 2026
Inflammaging and bone remodeling imbalance in osteoporosis
The review describes osteoporosis as a common age-related skeletal disorder with low bone mass, deteriorated bone microarchitecture and increased susceptibility to fragility fractures. It argues that current antiresorptive and anabolic therapies do not fully address aging-related biological processes. Evidence from osteoimmunology, immunosenescence and cellular senescence research suggests inflammaging contributes to age-related bone loss by reshaping the bone marrow immune microenvironment. Immune cells with senescence-associated features may promote remodeling imbalance through senescence-associated secretory phenotype factors such as interleukin-1β, interleukin-6, tumor necrosis factor-α, chemokines, matrix-degrading enzymes and receptor activator of nuclear factor-κB ligand. These mediators are described as enhancing osteoclast differentiation and survival, impairing osteoblast function, suppressing osteogenic differentiation of bone marrow mesenchymal stromal cells and propagating paracrine senescence in the bone marrow niche.
Supporting source [1]
Preclinical senolytic results and unresolved target cells
Senolytics are described as pharmacological agents that selectively induce apoptosis in senescent cells by targeting senescent-cell anti-apoptotic pathways. Preclinical studies, including those using dasatinib plus quercetin, fisetin and bone-targeted delivery platforms, reportedly reduced global senescent-cell burden, attenuated senescence-associated secretory phenotype-related inflammation and improved certain skeletal parameters in models of aging, postmenopausal osteoporosis and radiotherapy-associated bone loss. The review states it remains unclear whether these benefits arise from elimination of immune cells with senescence-associated features, stromal cells, osteocytes or a combination. Critically, it says direct evidence is lacking that currently available senolytics selectively eliminate senescence-associated immune-cell subsets within osteoporotic bone marrow.
Supporting source [1]
Early clinical evidence and proposed research roadmap
The review reports that early clinical evidence supports feasibility and hypothesis generation but does not yet establish senolytics as routine osteoporosis therapy. It proposes a structured research roadmap centred on fate-mapping, lineage-specific depletion and single-cell multi-omics to convert the prevailing hypothesis into experimentally testable and clinically actionable evidence, while outlining translational challenges that must be overcome to achieve precision senolytic therapy.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a narrative review, not a new study. Preclinical findings come from animal models and do not show human lifespan or fracture benefits. It is unclear which cell types mediate the reported effects, and direct evidence for selective removal of senescent immune-cell subsets in osteoporotic bone marrow is lacking. The proposed roadmap is a proposal, not a validated therapy.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zhu M, Zhang J, Fang H, Cai K, Wu Q, Gao C, Wang Y, Chen J. · europepmc.org · August 24, 2026